易瑞沙联合NP方案治疗晚期肺腺癌的临床观察

《易瑞沙联合NP方案治疗晚期肺腺癌的临床观察》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、NP方案序贯易瑞沙治疗晚期肺腺癌的临床观察456550河南林州林州市人民医院放疗科牛永健［摘要］背景与目的：晚期肺腺癌患者的治疗是多以化疗为主的全身治疗，口前尚无标准的治疗方案。本研究旨在观察晚期肺腺癌在常规NP方案化疗(4・6周期)后序贯易瑞沙(靶向治疗)治疗对患者生存率及生存质量的影响。方法：2009年1月—2011年1月经病理证实符合入选标准的15例晚期肺腺癌患者，接受NP方案化疗(4・6周期)后序贯易瑞沙治疗，治疗结束后按照实体瘤疗效评价标准(RECIST1.0)评价疗效，化疗结朿后3・4周开始口服易瑞沙。结果：15例患者中，13例

2、患者按规定完成4周期以上方案，总体PR5例，SD4例,PD4例，RR为38.4%(5/13),DCR69.2%(9/13),中位PFS6月，中位OS为11.8月。与易瑞沙相关的不良反应以皮疹、腹泻多见，其中多为0、I、II级，III、IV级少见。结论：NP方案序贯易瑞沙治疗晚期肺腺癌可提高一定的生存率及生存质量，安全有效，临床收益率高，是临床上值得推广的有应用前景的治疗方法。［关键词］NP方案；易瑞沙；晚期肺腺癌；联合化疗ClinicaleffectofNPregimenincombinationwithsequentialIressain

3、thetreatmentofadvancedadenocarcinomaofthelungNiuYong-jian,thePeopledHospitalofLinzhoucity,Linzhou456550,China【Abstract】Objctive:Thetreatmentofadvancedadenocarcinomaofthelungisdependentonthechemotherapyofallbody,uptonowthereisstillnostandardregimenoftherapy.Thisstudyaimsato

4、bservingthesurvivalrateandqualityonNPregimen(4〜6cycles)incombinationwithsequentialIressainthetreatmentofadvancedadenocarcinomaofthelung.Methods:FromJan.2009toJan.2011,atotalof15patientswithadvancedadenocarcinomaofthelungreceivedIressaandchemotherapy.Theefficacywasestimated

5、byRICISTevaluationstandardevery4〜6cycles,Iressawastakenorallyafter3〜4weeksfromchemotherapyend.Results:Inatotalof15patients,13patientshadreceivedchemotherapybeyond4cycleso5patientswerePR,4patientswereSD,4patientswerePD,theobjectiveresponseratewas38.4%,anddiseasecontrolratew

6、as69.2%.ThePFSwas6.0monthsandOSwas11.8months.ThemostcommonlyadverseeventsofIressawererashanddiarrhea・Mostweredegree0、I>IIanddegreeII1>IVwererare.Conclusion:NPregimenincombinationwithsequentialIressainthetreatmentofadvancedadenocarcinomaofthelungcouldincreasethecertainsurvi

7、valrateandqualityjtwaseffectiveandsafetyofcombinedIressawithchemotherapysequentialIressainthetreatmentofadvancedadenocarcinomaofthelung.[Keywords]NPregimen;Iressa;advancedadenocarcinomaofthelung;chemotherapy晚期肺腺癌化疗方案中多采用含钳类二联方案如：NP（长春瑞滨+顺钳）、TP（多西他赛+顺钳）、GP（吉西他滨+顺钳）、EP（依托泊昔+

8、顺钳）、PP（紫杉醇+顺钳）等等,对于疾病进展者，尚无资料证明孰优孰劣，目前尚无标准的治疗方案。本研究以NP（长春瑞滨+顺钳）方案为主序贯易瑞沙治疗晚期肺腺癌。笔者回顾性研究了本